References
- Adjei, A. A., C. Erlichman, J. N. Davis, D. L. Cutler, J. A. Sloan, R. S. Marks, L. J. Hanson, P. A. Svingen, P. Atherton, W. R. Bishop, P. Kirschmeier, and S. H. Kaufmann. 2000. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60, 1871-1877.
- Agrawal, A. G. and R. R. Somani. 2009. Farnesyltransferase inhibitor as anticancer agent. Mini Rev. Med. Chem. 9, 638-652. https://doi.org/10.2174/138955709788452702
- Ashar, H. R., L. James, K. Gray, D. Carr, M. McGuirk, E. Maxwell, S. Black, L. Armstrong, R. J. Doll, A. G. Taveras, W. R. Bishop, and P. Kirschmeier. 2001. The farnesyl transferase inhibitor SCH 66336 induces a G(2)--> M or G(1) pause in sensitive human tumor cell lines. Exp. Cell Res. 262, 17-27. https://doi.org/10.1006/excr.2000.5076
- Ashby, M. N. 1998. CaaX converting enzymes. Curr. Opin. Lipidol. 9, 99-102. https://doi.org/10.1097/00041433-199804000-00004
- Barbacid, M. 1987. Ras genes. Annu. Rev. Biochem. 56, 779-827. https://doi.org/10.1146/annurev.bi.56.070187.004023
- Basso, A. D., A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier. 2005. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 280, 31101-31108. https://doi.org/10.1074/jbc.M503763200
- Basso, A. D., P. Kirschmeier, and W. R. Bishop. 2006. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47, 15-31. https://doi.org/10.1194/jlr.R500012-JLR200
- Bos, J. L. 1989. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
- Bourne, H. R., D. A. Sanders, and F. McCormick. 1990. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348, 125-132. https://doi.org/10.1038/348125a0
- Chiu, V. K., T. Bivona, A. Hach, J. B. Sajous, J. Silletti, H. Wiener, R. L. 2nd. Johnson, A. D. Cox, and M. R. Philips. 2002. RAS signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343-350.
- Gibbs, J. B., A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77, 175-178. https://doi.org/10.1016/0092-8674(94)90308-5
- Glomset, J. A. and C. C. Farnsworth. 1994. Role of protein modification reactions in programming interactions between RAS-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10, 181-205. https://doi.org/10.1146/annurev.cb.10.110194.001145
- Han, J. Y., S. H. Oh, F. Morgillo, J. N. Myers, E. Kim, W. K. Hong, and H. Y. Lee. 2005. Hypoxia-inducible factor 1a and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl. Cancer Inst. 97, 1272-1286. https://doi.org/10.1093/jnci/dji251
- Hanrahan, E. O., M. S. Kies, B. S. Glisson, F. R. Khuri, L. Feng, H. T. Tran, L. E. Ginsberg, M. T. Truong, W. K. Hong, and E. S. Kim. 2009. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am. J. Clin. Oncol. 32, 274-279. https://doi.org/10.1097/COC.0b013e318187dd57
- Lantry, L. E., Z. Zhang, R. Yao, K. A. Crist, Y. Wang, J. Ohkanda, A. D. Hamilton, S. M. Sebti, R. A. Lubet, and M. You. 2000. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21, 113-116. https://doi.org/10.1093/carcin/21.1.113
- Lowy, D. R. and B. M. Willumsen. 1993. Function and regulation of ras. Annu Rev. Biochem. 62, 851-891. https://doi.org/10.1146/annurev.bi.62.070193.004223
- Malumbres, M. and M. Barbacid. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465. https://doi.org/10.1038/nrc1097
- Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der, and A. S. Jr. Baldwin. 1997. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812-1815. https://doi.org/10.1126/science.278.5344.1812
- Nagasu, T., K. Yoshimatsu, C. Rowell, M. D. Lewis, and A. M. Garcia. 1995. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55, 5310-5314.
- O'Regan, R. M. and F. R. Khuri. 2004. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocr. Relat. Cancer 11, 191-205. https://doi.org/10.1677/erc.0.0110191
- Oh, S. H., W. Y. Kim, J. H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, and H. Y. Lee. 2006. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 653-661. https://doi.org/10.1158/1078-0432.CCR-05-1725
- Satoh, T., M. Nakafuku, and Y. Kaziro. 1992. Function of Ras as a molecular switch in signal transduction. J. Biol. Chem. 267, 24149-24152.
- Whyte, D. B., P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. Bishop, and J. K. Pai. 1997. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464. https://doi.org/10.1074/jbc.272.22.14459
- Winter-Vann, A. M. and P. J. Casey. 2005. Post-prenylation-processing enzymes as new targets in oncogenesis. Nature Rev. Cancer 5, 405-412. https://doi.org/10.1038/nrc1612